Immunoregulatory Mechanisms of Treg Cells Induced by Tocilizumab

• Status: Completed
• Trial end date: 2018-10-01
• Target enrollment: 0
• Participant gender: All

Summary

We can speculate that the best responders to tocilizumab should have multiple related elements (Treg CD39, adenosine, IL-35) successfully induced and expressed in order to play its beneficial role. The study of these elements and its pathways could help identify the best responders to tocilizumab treatment.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
• Treatments: Adalimumab

Criteria

Inclusion Criteria:

• Patients of all sexes, aged ≥ 18 years.

• RA Patients (according to ACR / EULAR criteria 2010) of moderate to severe activity (DAS 28> 3.2 or SDAI> 11), and 6 months or more of evolution, starting treatment with ACTEMRA (tocilizumab) or with an anti-TNF, according to the product data.

• Patients with body weight ≤ 150 kg.

• Patients who have received written information about the study and gave their informed consent to participate in the study

Exclusion Criteria:

• Patients with a history of autoimmune disease or inflammatory joint disease other than RA.

• Patients treated with any investigational agent within 4 weeks (or 5 half-lives of investigational agent, whichever is greater) before starting treatment with tocilizumab